- Bayer AG (BAYN) remains exposed to extensive Roundup litigation: about 200,000 cases filed, roughly 60,000 pending, with plaintiffs adding design‑defect and misrepresentation claims.
- Jefferies lifted Bayer AG (BAYN) price target to €46 from €40 after a US Supreme Court win in Roundup litigation. Shares traded near €47.06; dividend outlook tied to debt and pharma deals.
- Bayer AG says pharma sales to be driven by asundexian plus Kerendia, Lynkuet and Beyonttra, with revenue growth expected through 2027–2032.
TradingView
Key facts: Bayer ~200k Roundup suits; PT €46; Pharma fuels 2027–32
Bayer AG (BAYN) remains exposed to extensive Roundup litigation: about 200,000 cases filed, roughly 60,000 pending, with plaintiffs adding design‑defect and misrepresentation claim